NAMIKENOSHA.org - Providing Support, Education, and Advocacy since 1983
NAMI Kenosha County
  • HOME
    • JOIN
    • DONATE
    • The Board - About Us
    • Affiliate Certification, By-Laws & Budget
    • History
    • Newsletter
  • SUPPORT
    • I NEED HELP - LOCAL CRISIS CONTACTS >
      • Local Area Services >
        • Rogers Memorial Hospital - Outpatient/Partial Inpatient
        • KHDS - Information Please!
        • Counseling Services in Kenosha
        • Kenosha Community Resource Booklet
        • Kenosha County Grief Guide
        • Kenosha Mental Health Guide
        • YMCA Program
        • Telepsychiatry
    • Inpatient Hospitals
    • National Crisis Hotlines >
      • Crisis Guide and Resources
    • Drug and Alcohol Addiction Local Support >
      • Substance Abuse Treatment help for Kenosha County
      • Rehab Accreditation
      • Kenosha County Opioid Task Force
      • Addiction is a Family Disease
      • NARCAN (Naloxone)
    • Online Support Resources
    • Bridges
    • Students
    • Suicide Prevention & Grief Support
    • Caregivers & Parents
    • Veterans
    • Mental Health Providers and Services
    • Physician Mental Health
    • Oxford House
    • Finding A Therapist
    • Law Enforcement
    • Faith Leaders
    • Psychiatric Service Dogs
    • Equine Therapy
    • NAMI AIR app
    • Holiday Blues
    • Cooling Centers
  • EDUCATION
    • RESOURCE LINKS >
      • Magazine List
      • Book List
      • Movie List
      • Documentary List
      • Music List
    • Family To Family
    • NAMI Basics
    • Ending The Silence
    • In Our Own Voice >
      • Voices of Recovery
    • CIP/CIT >
      • CIP/CIT Class Presentations
      • CIP/CIT Supplemental Class Materials
      • SAMHSA's GAIN CENTER
    • Homefront Classes
    • What is Mental Illness? >
      • Addiction and Dual Diagnosis
      • ADHD
      • ​Anosognosia
      • Anxiety Disorder
      • Bereavement/Grief, Anxiety and Depression
      • Bipolar Disorder
      • Borderline Personality Disorder
      • Children and Adolescents
      • Depression
      • Disruptive Mood Dysregulation Disorder
      • Dissociative Disorder
      • Eating Disorders
      • Obsessive Compulsive Disorder
      • Oppositional Defiant Disorder (ODD) / Conduct Disorder (CD)
      • PANS & PANDA Disorder
      • Pregnancy and Postpartum Depression
      • Post Traumatic Stress Disorder
      • Early Psychosis and Psychosis
      • Schizoaffective Disorder
      • Schizophrenia
      • Seasonal Affective Disorder (SAD)
      • Self Harm
      • Serious Mental Illness (SMI)
      • Hygiene and Mental Illness
      • Sleep and Mental Health
      • Tardive Dyskinesia
    • Death, Traumas, Disasters & Mental Health
    • Testing for Mental Illness
    • Mental Illness Dictionary
    • Mental Health Medication
    • Medication Withdrawal
    • Medications and Summer Heat Risks
    • Mood and The Pill
    • Benefits of Exercise
    • Alternative Treatments
    • Diet and Mental Health
    • Supplement, Food, Marijuana & Herb Interactions with Medication
    • Drug Duration in the Body
    • Certified Peer Specialist Training
    • Webinars
    • Famous People with Mental Issues
    • Popular in Social Media
  • ADVOCACY
    • Mental Health System: Kenosha County, Wisconsin >
      • Kenosha County Treatment Court
      • Kenosha County Behavioral Health Jail Diversion Program
      • Kenosha County Family Treatment Court
      • Veteran Treatment Court
      • Criminal Justice System
    • Chapter 51: Mental Commitments
    • Chapter 55: Protective Service
    • Workplace Mental Health
    • Health Insurance and Medicaid
    • Medicare
    • Psychiatric Advanced Directive
    • Research
    • Kenosha In The News
    • Local Heroes
    • Treatment Advocacy Center
    • STIGMA
    • Voting Rights
    • Policy and Issues
    • Government Shutdown
    • Get Involved
    • Mass Shootings and Violence
    • Voices in Action
    • Legislation >
      • S. 2661 988 Suicide Hotline
      • AB693 – Teacher Protection Act
      • HR 2792
      • Protect Medicaid
      • AHCA
      • H.R. 2646, Families in Mental Health Crisis Act
      • S2680, the Mental Health Reform Act of 2016
    • NAMI Smarts
    • NAMI 100 Women
  • EVENTS
    • Annual Vigil

Tardive Dyskinesia

movementdisorderschecklist.pdf
File Size: 236 kb
File Type: pdf
Download File

FDA Approves Medications For Tardive Dyskinesia
By Ken Duckworth, M.D. | Sep. 28, 2017

Tardive dyskinesia (TD) is a movement disorder that occurs in some people who take first-generation antipsychotics (such as haloperidol, chlorpromazine), and to a lesser degree, second-generation antipsychotics (such as aripiprazole or paliperidone). TD results in repetitive, involuntary movements commonly of the face, lips and limbs.
Movement disorders were first described in people experiencing schizophrenia before the advent of first-generation antipsychotics, but the clear majority of these movement symptoms currently are induced by medicines. TD can be disabling and stressful and it had no FDA-approved treatment—until recently.

Earlier this year, the FDA approved a new medication for the treatment of TD with the trade name Ingrezza and generic name valbenazine. The FDA fast-tracked this medicine’s approval process, given TD’s unmet treatment need. The clinical trial that led to the approval evaluated the movements of 234 individuals with TD who were also diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder. These research subjects were randomly assigned valbenazine or a placebo (a sugar pill).  At six weeks, a clear difference emerged in the movement symptoms of the two groups, which led to the approval.

Another medication recently also received FDA-approval for the treatment of TD in adults. With the trade name Austedo and generic name deutetrabenazine, this medication was previously approved (in April 2017) for the treatment of chorea associated with Huntington’s disease. This second-indication approval was based on results from two randomized controlled group studies that found Austedo to be effective and safe in reducing the severity of abnormal involuntary movements associated with TD.

If you have TD, these medications are worth a fresh conversation with your prescriber. In study trials, these medicines appear to be well-tolerated, though as with most treatments, there are common and serious side effects (usually for people with heart rhythm issues).

The clinical focus for TD to date has been largely on prevention, which hasn’t very successful given its prevalence. Doctors assess TD symptoms with the Abnormal Involuntary Movement Scale (AIMS) scale. This should be performed on a regular basis (typically every 6 months). The AIMS exam is an assessment of a person for movements that could suggest TD; if TD is suspected, a discussion about lowering medication dosage or switching medication to one with less risk is typically advised.  

TD can be avoided in some cases, but with long-term use of the medicine (tardy or emerging over time), the risks are increased. It’s hard to predict who will develop TD, but we do know that African-American, Asian-American, people with diabetes and individuals over 55 are at a greater risk. Many people take antipsychotics for decades, so the risk of developing TD is real and needs to be weighed against the benefits for symptom reduction and alternative treatments.
I have felt a bit helpless in the past when I see people who experience TD. We didn’t have any treatment options approved by the FDA. But now we have two new tools and I look forward to learning more about these medications from my patients’ experiences and scientific literature.

Ken Duckworth is medical director at NAMI.
Proudly powered by Weebly